Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05319600
Other study ID # STUDY00001482
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 23, 2022
Est. completion date July 20, 2023

Study information

Verified date March 2024
Source University of Vermont
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project is comprised of a two-arm randomized control trial (RCT) testing the feasibility, acceptability, and preliminary efficacy of a nationally scalable program, Activate, a 12-week, technology-delivered diabetes behavior-change skills training and physical activity promotion program for adolescents with type 1 diabetes. The researchers have a recruitment goal of 30 participants, but will enroll beyond 30 to address any withdrawal and ensure sample size is met. A primary goal of the study is assessing the feasibility and acceptability of the program, which combines two previously piloted components. Then, the investigators will compare the 12-week Activate program to a treatment as usual control group on proximal outcomes of behavior-change skills and daily active minutes. The investigators will also explore the impact of the Activate program on secondary mechanisms and outcomes linked with later type 1 diabetes health disparities: adolescent diabetes behavior regulation, psychological distress, inflammation, glycemic outcomes, and cardiovascular disease risk. It is hypothesized that a diabetes behavior-change skills training and physical activity intervention will be acceptable, and effective at improving behavior-change skills and daily active minutes, as well as other mechanisms and outcomes linked with later type 1 diabetes health disparities.


Description:

Adolescents with type 1 diabetes and socioeconomic disadvantage experience significant health disparities in glycemic outcomes in adolescence and cardiovascular disease and diabetes-related death later in adulthood. Socioeconomic disadvantage is associated with elevated glycosylated hemoglobin (HbA1c) and 3x risk of repeat hospitalizations for diabetic ketoacidosis as well as 2-3x risk of cardiovascular disease and diabetes-related death. Suboptimal glycemic outcomes are a powerful determinant of long-term health complications and costs, with a 1% reduction in HbA1c contributing to up to a 40% reduction in risk for later nephropathy, retinopathy, and macrovascular disease. Given the substantial health disparities for persons with type 1 diabetes and socioeconomic disadvantage and the many challenges that adolescents face with achieving optimal glycemic levels (<20% nationally meet American Diabetes Association HbA1c targets), this is a critical population to support in health behavior change via psychosocial intervention during adolescence. Unfortunately, existing evidence-based psychosocial type 1 diabetes interventions for adolescents, including robust multi-system approaches, have demonstrated limited efficacy for behavior change that results in improved glycemic outcomes and none have directly targeted cardiovascular health outside of glycemic outcomes. In this project, the researchers pursue a new avenue for intervention innovation by testing a nationally-scalable diabetes behavior-change skills training and physical activity intervention program to improve glycemic outcomes and decrease cardiovascular disease risks for adolescents with type 1 diabetes including those with socioeconomic disadvantage . In this study the researchers will conduct a two-arm randomized trial with 30 adolescents with type 1 diabetes, comparing the 12-week Activate program to a treatment-as-usual control group. This study has 2 primary aims. First, the investigators will assess acceptability of the Activate program by examining participant engagement with the Activate program components. To assess the preliminary efficacy of the Activate program the investigators will examine changes in proximal outcomes of behavior-change skills (goal setting, problem-solving, and coping skills), and active minutes compared between treatment and control groups from baseline to a 12-week follow-up assessment. Second, the investigators will explore the impact of the Activate program on secondary mechanisms and outcomes linked with longer-term type 1 diabetes health disparities.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date July 20, 2023
Est. primary completion date July 20, 2023
Accepts healthy volunteers No
Gender All
Age group 13 Years to 17 Years
Eligibility Inclusion Criteria: - Aged 13-17 years old - At least 18 months post-diagnosis for type 1 diabetes - Parent reported moderate to no physical activity for adolescent - Ability to complete measures and intervention program in English - Access to broadband or cellular internet - Resides in and receives healthcare in the United States Exclusion Criteria: - Ward of state - Active psychosis - Severe medical or psychiatric illness that limit participation (including any contraindications for physical activity)

Study Design


Intervention

Behavioral:
Diabetes behavior change skills training
Behavior-change skills training will be provided through eight web-delivered content and activity sessions across the 12-week program. Sessions 1 through 4 will occur weekly and sessions 5 through 8 biweekly. Each session takes approximately 15-20 minutes for the adolescent to complete both content learning and related activities. These learning sessions focus on skills like problem solving and goal setting.
Physical activity promotion program
The physical activity incentives program includes 12 weeks of personalized goals and incentives for increasing physically active minutes along with weekday text-based support. Active minutes, defined as minutes with moderate to vigorous physical activity, will be tracked via a Garmin fitness activity tracker.

Locations

Country Name City State
United States University of Vermont Burlington Vermont

Sponsors (1)

Lead Sponsor Collaborator
University of Vermont

Country where clinical trial is conducted

United States, 

References & Publications (8)

Clements MA, Foster NC, Maahs DM, Schatz DA, Olson BA, Tsalikian E, Lee JM, Burt-Solorzano CM, Tamborlane WV, Chen V, Miller KM, Beck RW; T1D Exchange Clinic Network. Hemoglobin A1c (HbA1c) changes over time among adolescent and young adult participants in the T1D exchange clinic registry. Pediatr Diabetes. 2016 Aug;17(5):327-36. doi: 10.1111/pedi.12295. Epub 2015 Jul 8. — View Citation

Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86. doi: 10.1056/NEJM199309303291401. — View Citation

Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr. 1994 Aug;125(2):177-88. doi: 10.1016/s0022-3476(94)70190-3. — View Citation

Ellis DA, Templin T, Naar-King S, Frey MA, Cunningham PB, Podolski CL, Cakan N. Multisystemic therapy for adolescents with poorly controlled type I diabetes: Stability of treatment effects in a randomized controlled trial. J Consult Clin Psychol. 2007 Feb;75(1):168-74. doi: 10.1037/0022-006X.75.1.168. — View Citation

Hood KK, Rohan JM, Peterson CM, Drotar D. Interventions with adherence-promoting components in pediatric type 1 diabetes: meta-analysis of their impact on glycemic control. Diabetes Care. 2010 Jul;33(7):1658-64. doi: 10.2337/dc09-2268. — View Citation

Menzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, Neumann PJ. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm. 2010 May;16(4):264-75. doi: 10.18553/jmcp.2010.16.4.264. — View Citation

Stanger C, Lansing AH, Scherer E, Budney A, Christiano AS, Casella SJ. A Web-Delivered Multicomponent Intervention for Adolescents with Poorly Controlled Type 1 Diabetes: A Pilot Randomized Controlled Trial. Ann Behav Med. 2018 Nov 12;52(12):1010-1022. doi: 10.1093/abm/kay005. — View Citation

Wood JR, Miller KM, Maahs DM, Beck RW, DiMeglio LA, Libman IM, Quinn M, Tamborlane WV, Woerner SE; T1D Exchange Clinic Network. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care. 2013 Jul;36(7):2035-7. doi: 10.2337/dc12-1959. Epub 2013 Jan 22. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in Coping Skills Assessed by the Coping Self-Efficacy Scale Assesses adolescents' coping skill self-efficacy. Indexes participants confidence in using different strategies to cope with challenges in daily life. The Coping Self-Efficacy Scale includes 26-items rated on an 11-point scale (0 ('cannot do at all'), 5 ('moderately certain can do') and 10 ('certain can do')). Higher scores indicate higher coping self-efficacy. week 1 and week 12
Primary Change from Baseline in Goal Setting Assessed by Goal-Directed Planning Participants will be asked to identify their most important diabetes, academic, social, and career/family goals. Following this, participants will be asked to identify which of their three non-diabetes goals most interfered with their diabetes goal. Participants will also complete the four-item planning subscale from the Goal System Assessment Battery to determine goal-directed planning activity for both their diabetes goal and their interfering goal identified in the goal assessment. The Goal System Assessment Battery is rated on a 5-point scale (1 = not at all true, 5 = extremely true). Higher scores indicated higher goal directed planning. Average levels of goal-directed planning will be used as the outcome variable for goal setting. week 1 and week 12
Primary Change from Baseline in Physical Activity The Garmin fitness activity tracker tracking will be used to determine the average number of daily minutes with moderate to vigorous physical activity, metabolic equivalents (METs) greater than or equal to 3 METs. daily for all days from week 1 through week 12
Secondary Change from Baseline in Self-Regulation Assessed by The Functional Assessment of Maladaptive Behaviors Assesses perceptions of the extent to which a person's behavior was sensitive to a particular reinforcer by rating 8 statements regarding the function of the behavior on a 4-point scale (0 = never, 3 = often). Higher scores indicate higher diabetes self-regulation. week 1 and week 12
Secondary Change from Baseline in Self-Regulation Assessed by the Diabetes Habit Strength (DHS) Measure Measures perceived habitual responding for glucose checking, insulin dosing, and carbohydrate counting and predicts daily treatment engagement in adolescents with type 1 diabetes. The Diabetes Habit Strength Measure includes 16 items on a 7-point scale (0 = strongly disagree, 7 = strongly agree). Higher scores indicate higher habit strength and thus higher self-regulation. week 1 and week 12
Secondary Change from Baseline in Self-Regulation Assessed by the Self Care Inventory (SCI) Measures diabetes treatment engagement. The Self Care Inventory includes 21 items about frequency of treatment engagement rated on a 5-point scale (0 = never, 5 = always). Higher scores indicate higher diabetes self care and thus higher self-regulation. week 1 and week 12
Secondary Change from Baseline in Self-Regulation Assessed by the Effortful Control Scale Short Measures challenges with self-regulation including inhibitory control, attention, and activation control. The Effortful Control Scale Short includes 16 items rated on a 5-point scale (1 = almost always untrue, 5 = almost always true). Higher scores indicate higher self-regulation. week 1 and week 12
Secondary Change from Baseline in Self-Regulation Assessed by the Delay Discounting Task Assesses preference for immediate over delayed rewards. The Delay Discounting Task includes 5 items. In each item participants will be asked if the'd prefer to receive $500 now or wait to receive $1000 after a specified delay in time. week 1 and week 12
Secondary Change from Baseline in Diet and Physical Activity Habit Strength Assessed by the Eating and Activity Behavioral Automaticity Scale (EABA) Measures perceived habitual responding for food and physical activity. The Eating and Activity Behavioral Automaticity Scale includes 14 items rated on a 7-point scale (1 = never, 7 = every time). Higher scores indicate higher diet and physical activity habit strength and thus higher self-regulation. week 1 and week 12
Secondary Change from Baseline in Distress Assessed by the Patient Health Questionnaire for Adolescents (PHQ-A) Measures how often participants have been bothered by specified symptoms of depression during the past two weeks. The Patient Health Questionnaire for Adolescents includes 8 items (excluding item 9 for suicidal ideation) rated on a 4-point scale (0 = not at all, 3 = nearly every day). Higher scores indicated higher distress. week 1 and week 12
Secondary Change from Baseline in Distress Assessed by the Pediatric Symptom Checklist (PSC-17) Indexes internalizing, externalizing, and attention symptoms in children. The Pediatric Symptom Checklist includes 17 items regarding the frequency of specified symptoms rated on a 3-point scale (never, sometimes, often). A score = 15 indicates a positive symptom score and thus higher distress. week 1 and week 12
Secondary Change from Baseline in Distress Assessed by the Motivation and Energy Inventory (MEI) Measures the extent of diminished engagement in reward motivated cognition, physical behavior, and social interactions. The Motivation and Energy Inventory includes 26 items rated on various scales (5-point scale 0 = never, 5 = everyday or nearly every day; 6-point scale 0 = never, 6 = all of the time; 5-point scale 0 = never, 5 = at least 7 times a week; 4-point scale 0 = not interested at all, 4 = extremely interested) which measure mental energy, physical energy, and social motivation. week 1 and week 12
Secondary Change from Baseline in Distress Assessed by the Perceived Stress Scale (PSS) Measures perceived stress; asks participants have often they've had certain feelings or thoughts during the past month. The Perceived Stress Scale includes 10 items rated on a 5-point scale (0 = never, 4 = very often). Higher scores indicate higher perceived stress. week 1 and week 12
Secondary Change from Baseline in Distress Assessed by the Diabetes Stress Questionnaire - Short Form (DSQ) Measures how stressful, upsetting, difficult, or much of a problem specified diabetes-specific stressors are. The Diabetes Stress Questionnaire - Short Form includes 24 items rated on a 4-point scale (0 = not at all, 3 = very much). Higher scores indicate higher diabetes stress. week 1 and week 12
Secondary Change from Baseline in Distress Assessed by the Type 1 Diabetes Quality of Life (T1DAL) Measure Measures diabetes-related quality of life by asking how often specified statements regarding diabetes are true. The Type 1 Diabetes Quality of Life measure includes 23 items rated on a 5-point scale (0 = no, not at all true, 5 = yes, very true). Higher scores indicate higher diabetes quality of life and thus lower distress. week 1 and week 12
Secondary Change from Baseline in Inflammation Assessed by C-Reactive Protein C-reactive protein will be measured through dried blood spot assay. week 1 and week 12
Secondary Change from Baseline in Glycosylated Hemoglobin (HbA1c) Percentage Measured through dried blood spot assay. week 1 and week 12
Secondary Change from Baseline in Mean Daily Blood Glucose (MBG) Assessed by participant report from diabetes device data from glucose meters and continuous glucose monitors (CGMs). This will include data from the 7 days prior to the baseline assessment and 7 days prior to the follow-up assessment. week 1 and week 12
Secondary Change from Baseline in Mean Variability in Blood Glucose Assessed by participant report from diabetes device data from glucose meters and continuous glucose monitors (CGMs). This will include data from the 7 days prior to the baseline assessment and 7 days prior to the follow-up assessment. week 1 and week 12
Secondary Change from Baseline in Cardiovascular Disease Risk Score Assessed by Weight Assessed per the American Heart Association Life's Simple 7 index, which includes weight. Cardiovascular health risks will be summarized through a single risk score. For each risk indicator, meeting ideal, intermediate, or poor health status will be associated with a score of 2 to 0, respectively, creating a 0 to 14 scale of cardiovascular disease risk. week 1 and week 12
Secondary Change from Baseline in Cardiovascular Disease Risk Score Assessed by Blood Pressure Assessed per the American Heart Association Life's Simple 7 index, which includes blood pressure. Cardiovascular health risks will be summarized through a single risk score. For each risk indicator, meeting ideal, intermediate, or poor health status will be associated with a score of 2 to 0, respectively, creating a 0 to 14 scale of cardiovascular disease risk. week 1 and week 12
Secondary Change from Baseline in Cardiovascular Disease Risk Score Assessed by Diet Assessed per the American Heart Association Life's Simple 7 index, which includes diet. Adolescents will report on diet habit using the standardized healthy diet questions from that match the American Health Association Healthy diet recommendations (intake of sodium, whole grains, fruits, vegetables, sugar-sweetened beverages, and fish) and they will report if they've tried or currently smoke. Cardiovascular health risks will be summarized through a single risk score. For each risk indicator, meeting ideal, intermediate, or poor health status will be associated with a score of 2 to 0, respectively, creating a 0 to 14 scale of cardiovascular disease risk. week 1 and week 12
Secondary Change from Baseline in Cardiovascular Disease Risk Score Assessed by Physical Activity Assessed per the American Heart Association Life's Simple 7 index, which includes physical activity. To measure physical activity, the Garmin fitness activity tracker tracking will be used to determine the average number of daily minutes with moderate to vigorous physical activity, metabolic equivalents (METs) greater than or equal to 3 METs, in week 1 and week 12. Cardiovascular health risks will be summarized through a single risk score. For each risk indicator, meeting ideal, intermediate, or poor health status will be associated with a score of 2 to 0, respectively, creating a 0 to 14 scale of cardiovascular disease risk. week 1 and week 12
Secondary Change from Baseline in Cardiovascular Disease Risk Score Assessed by Blood Sugar Assessed per the American Heart Association Life's Simple 7 index, which includes blood sugar. Assessed via glycosylated hemoglobin percentage through the dried blood spot assay. Cardiovascular health risks will be summarized through a single risk score. For each risk indicator, meeting ideal, intermediate, or poor health status will be associated with a score of 2 to 0, respectively, creating a 0 to 14 scale of cardiovascular disease risk. week 1 and week 12
Secondary Change from Baseline in Cardiovascular Disease Risk Score Assessed by Total Cholesterol Assessed per the American Heart Association Life's Simple 7 index, which includes cholesterol. Assessed through the dried blood spot assay. Cardiovascular health risks will be summarized through a single risk score. For each risk indicator, meeting ideal, intermediate, or poor health status will be associated with a score of 2 to 0, respectively, creating a 0 to 14 scale of cardiovascular disease risk. week 1 and week 12
Secondary Change in insulin requirements Assessed by participant report from diabetes device data from insulin pumps or injection logs. This will include data from the 7 days prior to the baseline assessment and 7 days prior to the follow-up assessment. week 1 and week 12
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02897557 - Insulet Artificial Pancreas Early Feasibility Study N/A
Completed NCT02750527 - Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany